FASCINATION ABOUT DO-264

quinupristin/dalfopristin will raise the stage or result of avanafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. CYP3A4 inhibitors might decrease avanafil clearance growing systemic publicity to avanafil; enhanced stages could lead to increased connected adverse activities; the maximum proposed dose of STEND